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Summary
 
Although it has been reported that activated platelets can adhere to intact endothelium, the re-
ceptors involved have not been fully characterized. Also, it is not clear whether activated plate-
lets bind primarily to matrix proteins at sites of endothelial cell denudation or directly to endo-
thelial cells. Thus, this study was designed to further clarify the mechanisms of activated platelet
adhesion to endothelium. Unstimulated human umbilical vein endothelial cell (HUVEC)
monolayers were incubated with washed, stained, and thrombin-activated human platelets. To
exclude matrix involvement, HUVEC were harvested mechanically and platelet binding was
measured by flow cytometry. Before the adhesion assay, platelets or HUVEC were treated with
different receptor antagonists. Whereas blockade of platelet 
 
b
 
1
 
 integrins, GPIb
 
a
 
, GPIV, P-selectin,
and platelet-endothelial cell adhesion molecule (PECAM)-1 did not reduce platelet adhesion to
HUVEC, blockade of platelet GPIIbIIIa by antibodies or Arg-Gly-Asp (RGD) peptides mark-
edly decreased adhesion. Moreover, when platelets were treated with blocking antibodies to
GPIIbIIIa-binding adhesive proteins, including fibrinogen and fibronectin, and von Willebrand
factor (vWF), platelet binding was also reduced markedly. Addition of fibrinogen, fibronectin,
or vWF further increased platelet adhesion, indicating that both endogenous platelet-exposed and
exogenous adhesive proteins can participate in the binding process. Evaluation of the HUVEC
receptors revealed predominant involvement of intercellular adhesion molecule (ICAM)-1 and
 
a
 
v
 
b
 
3
 
 integrin. Blockade of these two receptors by antibodies decreased platelet binding signifi-
cantly. Also, there was evidence that a component of platelet adhesion was mediated by endo-
 
thelial GPIb
 
a
 
.
 
 Blockade of 
 
b
 
1
 
 integrins, E-selectin, P-selectin, PECAM-1, vascular cell adhe-
sion molecule (VCAM)-1 and different matrix proteins on HUVEC did not affect platelet
adhesion. In conclusion, we show that activated platelet binding to HUVEC monolayers is
mediated by a GPIIbIIIa-dependent bridging mechanism involving platelet-bound adhesive pro-
teins and the endothelial cell receptors ICAM-1, 
 
a
 
v
 
b
 
3
 
 integrin, and, to a lesser extent, GPIb
 
a
 
.
 
A
 
lthough the pathophysiologic consequences of acti-
vated platelets in circulation are not yet fully under-
stood, it is well established that increased platelet activation
is associated with an enhanced risk of thrombotic compli-
cations in different clinical disorders, such as diabetes, pre-
eclampsia, unstable angina, peripheral vascular disease, and
stroke and after angioplastic and fibrinolytic therapy (1).
Because activated, but not resting, platelets have been shown
to adhere to intact endothelium, it has been suggested that
platelet thrombi may also occur in the absence of endothe-
lial cell denudation, particularly in the microvasculature (2–5).
However, while the platelet receptors involved in aggre-
gate formation and matrix adhesion have been studied ex-
tensively, the pathways responsible for the interaction of
platelets and the endothelium are not well characterized.
So far, three different platelet receptors have been re-
ported to be involved in the binding to endothelium. Roll-
ing of activated platelets on high endothelial venules was
found to depend primarily on platelet P-selectin (
 
a
 
IIb
 
b
 
3
 
;
CD62P; 6), whereas firm adhesion to human saphenous
vein endothelial cells was inhibited by anti-GPIIbIIIa (CD41a/
CD61) antibodies and RGD peptides (7). Furthermore,
it has been shown that platelet-sialylated glycoproteins
may, at least in part, be responsible for the increased adhesion
of platelets from diabetics to bovine valvular endothelial
cells (8).
Likewise, several distinct endothelial cell molecules have
been reported to be involved in the binding of resting and
activated platelets. Both endothelial-sialylated glycoproteins
(6), as well as P-selectin on activated endothelium (9), have
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been proposed to mediate platelet rolling. With human
umbilical vein endothelial cells (HUVEC)
 
1
 
 infected with
herpes virus or stimulated with IL-1 or plasma containing
chemotherapeutic drugs, platelet adhesion was effectively
inhibited by antibodies to endothelial von Willebrand fac-
tor (vWF) and 
 
a
 
v
 
b
 
3
 
 integrin (CD51/CD61), respectively
(10–12). Moreover, a recent in vivo study has presented
evidence that platelet–endothelial cell adhesion molecule-1
(PECAM-1; CD31) on endothelial cells may contribute to
platelet adhesion and aggregation at a site of injured but not
denuded endothelium (13).
Thus, this study was designed to further clarify the role
of the different receptors that have been implicated in the
adherence interaction of platelets with endothelial cells. Be-
cause both resting and activated platelets adhere primarily
to matrix proteins, rather than to endothelial cells, many in-
vestigators have used fixed endothelial cells in the adhesion
assay in an attempt to maintain complete confluence. How-
ever, fixation can alter the receptor function and does not
exclude the involvement of matrix proteins exposed by small
intercellular gaps or expressed on the endothelial cells them-
selves. Hence, to avoid this problem, platelet binding to
HUVEC was determined in suspension using flow cyto-
metry. Our results show that thrombin-activated platelets bind
to HUVEC by a GPIIbIIIa-dependent bridging mechanism
involving platelet-bound adhesive proteins, including fi-
brinogen, fibronectin, and vWF. Importantly, activated plate-
let binding did not involve endothelial cell–associated ad-
hesive proteins such as collagen IV, fibronectin, and vWF,
but instead used intercellular adhesion molecule-1 (ICAM-1;
CD54) and 
 
a
 
v
 
b
 
3
 
 integrin. In addition, we also found evi-
dence for the involvement of endothelial GPIb
 
a
 
 (CD42b).
Thus, these endothelial adhesion molecules may contribute
to the recruitment of activated platelets to intact endothelium
and, consequently, to the formation of intravascular platelet
aggregates, thereby promoting thrombotic processes.
 
Materials and Methods
 
Endothelial Cell Culture.
 
HUVEC were obtained by collage-
nase treatment of umbilical cord veins as previously described
(14). Cells were cultured on gelatin-coated dishes and propagated
in RPMI 1640 medium (BioWhittaker, Walkersville, MD) sup-
plemented with 20% bovine calf serum (Hyclone Laboratories
Inc., Logan, UT), 90 
 
m
 
g/ml heparin (Sigma Chemical Co., St.
Louis, MO), and 50 
 
m
 
g/ml endothelial cell growth factor prepared
from bovine hypothalamus (15). For flow cytometry assays, HUVEC
derived from passages two or three were allowed to grow to con-
fluence in 12-well dishes. For assays with HUVEC matrix, cells
were cultivated in 48-well plates and harvested with trypsin after
at least 4 d. Before the adhesion assay, HUVEC were washed
twice with RPMI medium and incubated with receptor antago-
nists in phenol red–free RPMI medium for 30 min at 37
 
8
 
C.
 
Platelet Preparation.
 
Blood was obtained by venipuncture from
healthy adult volunteers according to a protocol approved by the
Human Subjects Division of the University of Washington (Seat-
tle, WA). The volunteers did not take any drugs for the previous
10 d. Isolation of platelets was performed as described by Baen-
ziger and Majerus (16). In brief, blood was drawn into polypropylene
syringes containing one-tenth volume of 0.11 M sodium citrate
and centrifuged at 1,000
 
 
 
g
 
 for 4 min to obtain platelet-rich
plasma. Platelets were sedimented by centrifugation at 2,000 
 
g
 
 for
10 min and washed twice with 10 ml of Hepes buffer (10 mM
Hepes, 0.5 mM MgCl
 
2
 
, 130 mM NaCl, 4 mM KCl, 1 mM CaCl
 
2
 
,
and 5 mM glucose, pH 7.4). To pellet erythrocytes selectively,
platelets were resuspended in the same buffer and centrifuged
twice at 120
 
 
 
g
 
 for 3 min. Subsequently, the content of eryth-
rocytes was 
 
,
 
1% as calculated using a hemocytometer. Platelets
were stained with 2.5 
 
m
 
M calcein–acetoxymethyl ester (Molecu-
lar Probes Inc., Eugene, OR) in the dark for 15 min. To avoid
platelet activation, all centrifugations were done at room temper-
ature and in the presence of 1 
 
m
 
M prostaglandin E1 (Alprostadil,
Prostin VR Pediatric
 
Ò
 
; The Upjohn Co., Kalamazoo, MI). After
washing, platelets were adjusted to a final concentration of 2
 
 3
 
10
 
9
 
/ml and activated with 0.5 U/ml human thrombin (Sigma
Chemical Co.) for 10 min. Thrombin was inactivated with 2 U/ml
hirudin (Sigma Chemical Co.) for 10 min. Platelets were incu-
bated with receptor antagonists for 30 min at room temperature.
 
Antibodies.
 
To block 
 
b
 
1
 
 integrins (CD29), the mAb P4C10
(IgG
 
1
 
; GIBCO BRL, Gaithersburg, MD) was used. This mAb
blocks cell–cell as well as cell–matrix adhesion (17). The anti–human
 
a
 
v
 
b
 
3
 
 integrin mAb LM609 (IgG
 
1
 
; Chemicon International, Inc.,
Temecula, CA), blocks the RGD-binding site, whereas the anti–
human 
 
a
 
v
 
b
 
3
 
 integrin mAb LM142 (IgG
 
1
 
; Chemicon International
Inc.) is a nonblocking mAb (18). Platelet GPIIbIIIa was blocked
by the mAb P2 (IgG
 
1
 
; Immunotech Inc., Westbrook, ME) that
inhibits platelet binding to fibrinogen and thrombin-induced
platelet aggregation (19). Both anti–human GPIb
 
a
 
 mAbs, SZ2
(IgG
 
1
 
; Immunotech Inc.) and 2E4 (provided by Dr. G.J. Roth,
Veterans Affairs Medical Center, Seattle, WA) are blocking mAbs
that inhibit ristocetin-dependent binding of vWF to platelets and
ristocetin-induced platelet aggregation (reference 20 and our un-
published observation). The anti–human GPIX (CD42a) mAb
BL-H6 (IgG
 
1
 
; Sigma Chemical Co.) was used as a negative con-
trol for the GPIb–IX complex on platelets. Platelet GPIV (CD36)
was inhibited by the blocking mAb FA6.152 (IgG
 
1
 
; Immunotech
Inc.). ICAM-1 was tested by four different blocking mAbs. mAb
R6.5 (provided by Dr. R. Rothlein, Boehringer Ingelheim Phar-
maceuticals Inc., Ridgefield, CT) inhibits adhesion of neutrophils
to ICAM-1 by blocking the 
 
b
 
2
 
 integrin–binding site (CD18; ref-
erence 21). The mAbs 6E6 and 2D5 (provided by Dr. D.C. Al-
tieri, The Boyer Center for Molecular Medicine, Yale University
School of Medicine, New Haven, CT) block the 
 
b
 
2
 
 integrin- and
the fibrinogen-binding site of ICAM-1, respectively (22),
whereas the mAb VF27 (IgG
 
1
 
; Endogen Inc., Woburn, MA) in-
hibits adhesion of rhinoviruses to endothelial cells by blocking the
first Ig domain of ICAM-1 (23). P-selectin was tested by mAb
WAPS12.2 (IgG
 
1
 
; Endogen Inc.) and mAb G1 (IgG
 
1
 
; Biosource
Intl., Camarillo, CA) that block platelet rolling on endothelium
and platelet adhesion to neutrophils, respectively (6, 24). To
block E-selectin (CD62E), HUVEC were treated with the mAbs
1.2B6 (IgG
 
1
 
; Endogen) and H18-7 (IgG
 
2
 
; Becton Dickinson, San
Jose, CA) that both block leukocyte adhesion to stimulated en-
dothelial cells (25, 26). Vascular cell adhesion molecule-1
(VCAM-1; CD106) was blocked by the mAbs E1-6 (IgG
 
1
 
; Bec-
ton Dickinson) and 1G11 (IgG
 
1
 
; Immunotech Inc.). Both mAbs
 
1
 
Abbreviations used in this paper:
 
 HUVEC, human umbilical vein endothe-
lial cells; ICAM, intercellular adhesion molecule; PECAM, platelet en-
dothelial cell adhesion molecule; RGD, Arg-Gly-Asp; TEM, transmission
electron microscopy; TSP, thrombospondin; VCAM, vascular cell adhe-
sion molecule; vWF, von Willebrand factor. 
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inhibit leukocyte binding to stimulated endothelial cells (26, 27).
PECAM-1 was tested by the mAbs JC70A (IgG
 
1
 
; Accurate
Chemicals Co., Westbury, NY) and M89D3 (IgG
 
1
 
; provided by
Dr. M.R. Zocchi, Laboratory of Adoptive Immunotherapy, Mi-
lan, Italy). To block fibrinogen binding to GPIIbIIIa, platelets
were treated with the anti–human fibrinogen mAb D1G10VL2
(IgG
 
1
 
; Immunotech Inc.) that is directed to the GPIIbIIIa-bind-
ing D fragment. The anti–human fibronectin mAb type 2 (Calbio-
chem-Novabiochem Corp., La Jolla, CA) reacts with the cell at-
tachment site of fibronectin and inhibits ADP-induced platelet
aggregation (28). All of these mAbs were used at a final concen-
tration of 40 
 
m
 
g/ml. The anti–human collagen IV mAb COL-94
(IgG
 
1
 
) and the anti–human vWF rabbit polyclonal antibody (IgG
fraction; both Sigma Chemical Co.) were used at a final dilution
of 1:250. A nonspecific isotype control was performed with a
mouse IgG
 
1
 
k
 
 mAb (Sigma Chemical Co.).
 
Other Receptor Antagonists.
 
Gly-Arg-Gly-Asp-Ser (GRGDS) and
Gly-Arg-Gly-Glu-Ser (GRGES) peptides (Peninsula Laborato-
ries, Belmont, CA) and recombinant annexin V (provided by Dr.
J.F. Tait, University of Washington, Seattle, WA) were used at fi-
nal concentrations of 50 
 
m
 
g/ml and 5 
 
m
 
M, respectively. Treatment
with neuraminidase from Vibrio cholerae (Calbiochem-Nova-
biochem Corp.) was performed at a final concentration of 0.5 U/
ml for 4 h (platelets 60 min). For divalent cation depletion assays,
cells were incubated with 1 mM EDTA (Sigma Chemical Co.)
for 30 min. Adhesive proteins were added to HUVEC immedi-
ately before addition of platelets. Purified human vWF (American
Diagnostica Inc., Greenwich, CT), fibrinogen (Sigma Chemical
Co.), fibronectin (Calbiochem-Novabiochem Corp.), and bovine
albumin (Sigma Chemical Co.) were used at concentrations as in-
dicated in the figure legends. Ristocetin (Sigma Chemical Co.)
was added together with vWF at concentrations as indicated in
the figure legends.
 
Determination of HUVEC-associated Adhesive Proteins.
 
Washed,
suspended HUVEC were incubated with antibodies to either col-
lagen IV, fibronectin, or vWF (same antibodies as described
above) for 30 min. After washing twice, the secondary FITC-
conjugated antibody, either goat anti–mouse IgG (Caltag Lab.,
San Francisco, CA) or mouse anti–rabbit IgG (Sigma Chemical
Co.), was incubated for 30 min (final dilution of 1:200). At least
10,000 cells were then analyzed by a FACScan
 
Ò
 
 (Becton Dickin-
son). Cells treated with FITC-conjugated isotype-specific IgG
were used as negative controls.
 
Adherence Assay (Flow Cytometry).
 
HUVEC were washed twice
with RPMI medium and incubated with 600 
 
m
 
l of Hepes buffer
(same buffer as described above, but with 2 mM CaCl
 
2 
 
added)
and 40 
 
m
 
l of the suspension of activated and stained platelets for
30 min at 37
 
8
 
C. The final platelet concentration was 1.25
 
 3 
 
10
 
8
 
/
ml. After removing unbound platelets followed by two washes,
HUVEC were harvested mechanically by vigorous pipetting,
washed once, and then immediately fixed with 80% ethanol on
ice for 30 min. To differentiate HUVEC from residual unbound
platelets, HUVEC were stained with the DNA-binding dye pro-
pidium iodide. The cells were resuspended in 200 
 
m
 
l PBS buffer,
pH 7.4, and 0.1% Triton X-100 containing 5 
 
m
 
g/ml propidium
iodide and 50 
 
m
 
g/ml ribonuclease A (R-6513; all Sigma Chemi-
cal Co.). Subsequently, specimens were analyzed by a FACScan
 
Ò
 
.
At least 10,000 cells that stained positive for propidium iodide
(FL-2-H) were evaluated. Platelet adhesion to HUVEC was ex-
pressed by the median fluorescence (FL-1-H) of the entire HU-
VEC population. Based on the distribution of the DNA content
(FL-2-H), HUVEC were routinely tested for homotypic aggre-
gate formation. On average, 
 
z
 
5% of the cells exhibited more
than tretraploid DNA content indicating that they were clumped.
Statistical significance was determined using Student’s 
 
t
 
 test.
 
Adherence Assay (Fluorescence Plate Reader).
 
Assays of platelet
adhesion to HUVEC matrix were performed in 48-well dishes.
Platelets were isolated, stained, and activated as described above.
After harvesting the HUVEC with EDTA, 2.5
 
 3 
 
10
 
7
 
 platelets per
well were allowed to adhere to the matrix for 30 min at 37
 
8
 
C.
Adherence was then assessed in a Cytofluor Series 4000 fluores-
cence plate reader (PerSeptive Biosystems, Framingham, MA).
Plates were scanned before and after washing for total and adher-
ent cells, respectively. Adherence was expressed as a percentage of
the total fluorescence.
 
Transmission Electron Microscopy.
 
Adhesion assays were per-
formed as described above. HUVEC were then harvested, washed,
and fixed with 3% glutaraldehyde in PBS buffer. After postfix-
ation with 2% osmium tetroxide for 60 min, cells were washed
and dehydrated with increasing concentrations of ethanol and fi-
nally propylene oxide. Fragments of the cell pellet were infiltrated
with 100% Medcast in vacuum for 4 h and subsequently embed-
ded in 100% fresh (Ted Pella, Reading, CA) Medcast. After poly-
merization for 48 h at 60
 
8
 
C, specimens were visualized by a
JEOL 1200-EX11 (JEOL USA Inc., Peabody, MA).
 
Results
 
Time Course of Platelet Binding.
 
Over a time period of
30 min, the number of HUVEC with bound resting plate-
lets was quite low (Fig. 1). However, with thrombin-acti-
vated platelets HUVEC exhibited a significant increase in
fluorescence after only 5 min. Maximal binding of acti-
vated platelets was found after 20–30 min. As determined
by an arbitrary gate, 
 
z
 
10 and 65% of HUVEC bound rest-
ing and activated platelets, respectively. Using flow cytom-
etry, it was not possible to determine whether the increased
Figure 1. Time course of
platelet binding to HUVEC
monolayers. Washed and cal-
cein-loaded resting or thrombin-
activated platelets were allowed
to adhere to a HUVEC mono-
layer for 5 or 30 min. HUVEC
were then harvested and assayed
by flow cytometry to determine
platelet binding that is expressed
as Platelet binding (FL-1-H) of
the entire HUVEC population.
The shaded and open curves rep-
resent HUVEC incubated with
resting and activated platelets, re-
spectively. When estimated by
an arbitrary gate, HUVEC bound
resting and activated platelets by
z10 and 65% after 30 min, re-
spectively. As depicted by the
symbols A and B, the increased
fluorescence of HUVEC incu-
bated with activated platelets
may be due to either numerous
single platelets (symbol A) or
only one large aggregate (symbol
B). Using flow cytometry, it is
not possible to distinguish between these two mechanisms. A representa-
tive experiment of three performed is shown. 
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fluorescence of HUVEC was due to multiple single plate-
lets bound to HUVEC or to a few large platelet aggregates
attached to HUVEC. However, large platelet aggregate for-
mation on HUVEC was found to be a rare event (see be-
low), suggesting that the adhesive interaction was platelet–
HUVEC rather than platelet–platelet.
 
HUVEC Become Coated Mainly by Single Platelets.
 
The
striking difference in the fluorescence intensity between
HUVEC incubated with either resting or activated platelets
was also evident by transmission electron microscopy (TEM).
As shown in Fig. 2 
 
A
 
, resting platelets bound minimally to
HUVEC. However, activated platelets bound avidly to
HUVEC with single or clumped platelets coating the en-
dothelial cells (Fig. 2 
 
B
 
). Occasionally, large platelet aggre-
gates adherent to HUVEC could also be found (Fig. 2 
 
C
 
).
However, on average, we observed only one large aggre-
gate in every 10–12 samples.
 
Activated Platelets Bind to Different HUVEC Adhesion Mol-
ecules.
 
Treatment of HUVEC with annexin V, neuramini-
dase, and the blocking anti-
 
b1 mAb P4C10 did not affect
platelet adhesion (Fig. 3 A). When HUVEC were treated
with the anti–PECAM-1 mAb M89D3, platelet adhesion
decreased by z10%. However, this decrease was not signif-
icant. Although HUVEC were not stimulated by any ex-
ogenous agents before the assay, we also tested stimulation-
dependent HUVEC receptors, assuming that platelets
might be able to activate HUVEC. Blocking mAbs to
VCAM-1, E-selectin, or P-selectin did not inhibit platelet
binding. However, a significant decrease in platelet binding
was observed when HUVEC were treated with mAbs to
ICAM-1, avb3 integrin, or GPIba. All four mAbs to
ICAM-1 exhibited a blocking effect. HUVEC treated with
anti–ICAM-1 mAb R6.5 or 6E6, which both block the b2
Figure 2. TEM of HUVEC monolayers incubated with platelets. A illustrates two adherent HUVEC that were incubated with resting platelets. On
the entire circumference of the cell surfaces, there is only one area (black arrow) exhibiting adherent platelets (A). However, when incubated with acti-
vated platelets HUVEC were covered completely with single platelets (black arrow, B). Occasionally, large platelet aggregates were found (C). The magni-
fication is 1:5,000–6,000.
Figure 3. Platelet adhesion to HUVEC monolayers after blockade of
HUVEC receptors. Thrombin-activated platelets were allowed to adhere
to a HUVEC monolayer that was treated with either antagonists of differ-
ent endothelial cell adhesion molecules (A) or antibodies to adhesive pro-
teins (B). Platelet binding was then determined by flow cytometry as de-
scribed above. The following concentrations were used: 5 mM annexin
V, 0.5 U/ml neuraminidase, 50 mg/ml GRGES and GRGDS peptides, 1
mM EDTA, 40 mg/ml mAb, and a dilution of 1:250 for polyclonal anti-
bodies. Results are expressed as the mean 6 SD of the median fluores-
cence (FL-1-H) of at least four experiments. *P ,0.01 and **P ,0.05 by
Student’s t test, compared with activated platelet adhesion to HUVEC
treated with the isotype-specific control mAb.333 Bombeli et al.
integrin–binding site of ICAM-1, decreased platelet bind-
ing by z26%. Similarly, the mAb VF27, which has been
found to block adhesion of rhinoviruses to endothelial
ICAM-1, also reduced platelet binding by z32%. However,
the greatest inhibition (50%) was found when HUVEC
were treated with the mAb 2D5, which blocks the fibrino-
gen-binding site of ICAM-1 (22). Involvement of avb3
integrin was evident when platelet adhesion decreased
by z38% after treating HUVEC with the anti-avb3 inte-
grin mAb LM609, whereas the nonblocking anti-avb3 in-
tegrin mAb LM142 had no effect. Interestingly, the anti-
GPIba mAb SZ2 also exhibited an inhibitory effect, reducing
platelet binding significantly by z22%. A second blocking
anti-GPIba mAb 2E4 inhibited platelet adhesion by z12%,
which, however, was not statistically significant. Incubation
with RGD peptides and EDTA decreased platelet binding
by 60 and 71%, respectively. A combined treatment with
mAbs to ICAM-1 (2D5), GPIba (SZ2), and avb3 integrin
(LM609) decreased platelet adhesion by z59%, but still did
not reduce binding to the level of resting platelets.
Activated Platelets Do Not Bind to HUVEC-associated Ma-
trix Proteins. Platelets are well known to bind rapidly to
the adhesive proteins that are exposed by an injured vessel
wall. Thus, HUVEC were tested for the exposure of ma-
trix proteins known to be important for platelet adhesion,
such as collagen IV, fibronectin, and vWF. When analyzed
by flow cytometry, all three of these proteins were found
to be exposed on detached HUVEC with vWF staining
greater than fibronectin and collagen IV. Incubation of
HUVEC monolayers with the same antibodies to collagen
IV, fibronectin, and vWF did not affect platelet adhesion
(Fig. 3 B). However, each of the three antibodies was
found to inhibit platelet adhesion to a matrix of the corre-
sponding purified protein such as collagen IV, vWF, and fi-
bronectin (data not shown). This suggests that the HUVEC
monolayers do not express these adhesive proteins on the
luminal surface to a degree sufficient to contribute to plate-
let binding. Indeed, when platelets were allowed to adhere
to HUVEC in suspension, treatment of HUVEC with the
antifibronectin and anti-vWF mAb markedly decreased
platelet binding (data not shown). Thus, matrix proteins
relevant for platelet binding, such as fibronectin and vWF,
seem to be expressed primarily on the abluminal side of en-
dothelial cells.
Activated Platelets Bind to HUVEC Matrix via b1 Inte-
grins. To clarify further the role of matrix proteins in the
adhesion of activated platelets to HUVEC, we tested whether
the platelet receptors involved in the binding to HUVEC
were the same as those involved in the binding to the
HUVEC matrix. Measured by a fluorescence plate reader,
activated platelets bound exclusively by b1 integrins to the
HUVEC matrix (Fig. 4). Blockade of other receptors in-
cluding GPIba, GPIV, and GPIIbIIIa did not significantly
affect platelet adhesion. Similarly, platelet b1 integrins were
the primary receptors mediating the binding of activated
platelets to HUVEC in suspension (data not shown). How-
ever, platelet adhesion to adherent HUVEC monolayers
did not involve platelet b1 integrins (see below), which fur-
ther indicates that exposed matrix proteins on the HUVEC
monolayer did not serve as ligands for activated platelet re-
ceptors.
Activated Platelets Bind to HUVEC by GPIIbIIIa. As shown
in Fig. 5 A, thrombin-activated platelet adhesion to HU-
VEC was found to be mediated by the platelet receptor
GPIIbIIIa. Blockade of phosphatidlyserine by annexin V and
enzymatic degradation of sialylated glycoproteins by neur-
aminidase did not affect adhesion. As well, incubation of
platelets with mAbs to b1 integrins (clone P4C10), GPIba
(clones SZ2 and 2E4), GPIX (clone BL-H6), GPIV (clone
FA6.152), and P-selectin (clones G1 and WAPS12.2) did
not reduce platelet binding to HUVEC. Similar to HU-
VEC, treatment of platelets with the anti–PECAM-1 mAb
M89D3 led to a slight decrease of platelet binding, which,
however, was not significant. Because in separate experi-
ments we found that platelets did not bind to recombinant
PECAM-1 (our unpublished observation), involvement of
PECAM-1 in the interaction with HUVEC seemed very
unlikely. On the other hand, when platelets were treated
with either RGD peptides or the anti-GPIIbIIIa mAb P2,
platelet binding was reduced by .50%. Furthermore, EDTA
(which dissociates GPIIbIIIa) decreased platelet binding al-
most to the level of resting platelets. Because it was not
possible to remove the mAbs from the platelet suspension
after activation with thrombin (centrifugation would cause
Figure 4. Platelet adhesion to HUVEC matrix after blockade of plate-
let receptors. Thrombin-activated platelets treated with antagonists to dif-
ferent platelet receptors were allowed to adhere to HUVEC matrix for 30
min. Platelet binding was then determined by a fluorescence plate reader
as described above. The following concentrations were used: 40 mg/ml
for mAb and a dilution of 1:250 for polyclonal antibodies. Results are ex-
pressed as the mean 6 SD of the percentage of adherent platelets of at
least three experiments. *P ,0.01 by Student’s t test, compared with ad-
hesion of activated platelets treated with the isotype-specific control mAb.334 Activated Platelet Adhesion to Endothelial Cells
an irreversible clot), it was necessary to consider the possi-
bility that unbound mAbs could also block HUVEC receptors.
However, when using mAbs and peptides at concentrations
corresponding to the concentration in the platelet suspen-
sion after dilution in the adhesion buffer, platelet binding
was not affected (data not shown).
Platelet-associated Adhesive Proteins Mediate Binding to HU-
VEC Monolayers. Upon activation, platelets express dif-
ferent adhesive proteins, such as fibrinogen, fibronectin,
and vWF (28, 29). Because all three of these proteins are
known to mediate platelet aggregation, their involvement
in the binding to HUVEC seemed very likely. Indeed, as
shown in Fig. 5 B, blockade of vWF, fibrinogen, and fi-
bronectin on platelets decreased adhesion to HUVEC
monolayers by 56, 46, and 39%, respectively. This result
indicates that, similar to platelet aggregation, platelet-
exposed adhesive proteins participate in activated platelet
binding to HUVEC monolayers.
Exogenous Adhesive Proteins Enhance Platelet Binding to
HUVEC. To investigate further the role of adhesive pro-
teins in the binding mechanism, platelet adhesion was ex-
amined in the presence of purified fibrinogen, fibronectin,
vWF, and albumin (Fig. 6). All proteins but albumin were
found to induce a significant increase in platelet binding.
The minimal concentrations required for a maximal in-
crease were 75 mg/ml for fibrinogen, 15 mg/ml for fi-
bronectin, and 0.25 mg/ml for vWF, which correspond to
plasma concentrations of 2.5, 5, and 2.5%, respectively.
Addition of vWF increased platelet adhesion only in the
presence of ristocetin, but had no effect when added alone.
This indicates an involvement of endothelial and/or plate-
let GPIba. Participation of endothelial GPIba seemed
more likely, because blockade of GPIba on HUVEC, but
not platelets, was found to affect platelet adhesion (Figs. 4
A and 5 A). Albumin added at concentrations up to 4 mg/ml
did not alter platelet binding, confirming that the effect of
adhesive proteins was specific.
Activated Platelet Adhesion to HUVEC Requires Bridging
Molecules. Results to this point suggested that adhesive
proteins may play an important role in mediating the bind-
ing of activated platelets to HUVEC monolayers. This hy-
pothesis was further supported by experiments using zinc
or manganese, rather than thrombin, to activate platelets
Figure 5. Platelet adhesion to HUVEC monolayers after blockade of
platelet receptors. Thrombin-activated platelets treated with either antag-
onists to different platelet receptors (A) or antibodies to adhesive proteins
(B) were allowed to adhere to a HUVEC monolayer for 30 min. Platelet
binding was determined by flow cytometry as described above. The fol-
lowing concentrations were used: 5 mM annexin V, 0.5 U/ml neuramini-
dase, 50 mg/ml GRGES and GRGDS peptides, 1 mM EDTA, 40 mg/ml
mAb, and a dilution of 1:250 for polyclonal antibodies. Results are ex-
pressed as the mean 6 SD of the median fluorescence (FL-1-H) of at least
four experiments. *P ,0.01 and P ,0.05 by Student’s t test, compared with
adhesion of activated platelets treated with the isotype-specific control mAb.
Figure 6. Platelet adhesion to
HUVEC monolayers after addi-
tion of adhesive proteins.
Thrombin-activated platelets
were allowed to adhere to HU-
VEC monolayers for 30 min in
the presence of different adhesive
proteins. Platelet binding was
then determined by flow cytom-
etry as described above. The fol-
lowing concentrations were
used: 4 mg/ml albumin, 75 mg/
ml fibrinogen, 15 mg/ml fi-
bronectin, and 0.25 mg/ml vWF, which corresponded to a plasma con-
centration of 10, 2.5, 5, and 2.5%, respectively. Ristocetin was added to-
gether with vWF at a final concentration of 1 mg/ml. Results are
expressed as the mean 6 SD of the median fluorescence (FL-1-H) of at
least four experiments. **P ,0.05 by Student’s t test, compared with ad-
hesion without proteins.
Figure 7. Adhesion of resting
platelets to HUVEC monolayers
in the presence of zinc or man-
ganese. Resting platelets were al-
lowed to adhere to HUVEC
monolayers for 30 min in the
presence of 0.5 mM zinc (open
bars) or 2 mM manganese (filled
bars) with or without the addi-
tion of 375 mg/ml fibrinogen.
Both zinc and manganese acti-
vate platelets without inducing
secretion. Platelet binding was then determined by flow cytometry as de-
scribed above. Adhesion was also measured in the presence of 40 mg/ml
anti-GPIIbIIIa mAb P2 and antifibrinogen mAb D1G10VL2. Results are
expressed as the mean 6 SD of the median fluorescence (FL-1-H) of at
least three experiments. *P ,0.01 by Student’s t test, compared with ad-
hesion with fibrinogen.335 Bombeli et al.
(Fig. 7). Both cations are known to activate GPIIbIIIa with-
out inducing secretion and aggregation (30, 31). In the
presence of 0.5 mM zinc or 2 mM manganese only, plate-
lets did not adhere to HUVEC. However, when exoge-
nous fibrinogen (375 mg/ml) was added, both zinc- and
manganese-activated platelets bound to HUVEC to the
same degree as thrombin-activated platelets. Again, this
binding could be partly inhibited by the anti-GPIIbIIIa
mAb P2 and the antifibrinogen mAb D1G10VL2. Hence,
the ability of platelets to bind to HUVEC monolayers de-
pended not only on an activated GPIIbIIIa receptor, but
also on the presence of a bridging adhesive protein such as
fibrinogen.
vWF and Ristocetin Enhance Platelet Binding to HU-
VEC. Fig. 8 further demonstrates a GPIba-dependent
component of platelet adhesion to HUVEC. In the pres-
ence of 1 mg/ml vWF, ristocetin dose dependently in-
creased binding of resting and activated platelets. However,
when HUVEC were treated with the anti-GPIba mAb
SZ2, binding of resting and activated platelets decreased by
z30 and 23%, respectively. Treatment of resting platelets
with the mAb SZ2 reduced binding to HUVEC by z80%,
whereas treatment of activated platelets did not affect adhe-
sion significantly. This result indicates that the vWF/risto-
cetin-induced increase in the binding of resting platelets to
HUVEC depended on both platelet and endothelial GPIba,
whereas increased binding of activated platelets required only
endothelial GPIba.
Discussion
In this report we show that adherence of thrombin-acti-
vated platelets to HUVEC monolayers is mediated by plate-
let GPIIbIIIa and distinct endothelial cell adhesive mole-
cules (Fig. 9). As has previously been demonstrated (32),
flow cytometry is a very sensitive and accurate method to
measure heterotypic adhesion of platelets and its use al-
lowed us to exclude the involvement of matrix proteins in
the adhesive interaction.
Besides other mechanisms, activated platelet adhesion to
leukocytes and tumor cells has been found, similar to plate-
let aggregation, to involve fibrinogen bound to GPIIbIIIa
(33–35). Thus, it seemed very likely that the same mecha-
nism mediated platelet binding to endothelial cells. Indeed,
blockade of GPIIbIIIa by the mAb P2 or RGD peptides
decreased platelet binding to HUVEC monolayers by z50%,
which is comparable to a recent report (7). Although both
RGD peptides and the mAb P2 have been shown to block
completely platelet aggregation (19), platelet binding to
HUVEC was not inhibited 100% by these antagonists. Be-
cause platelets were activated before treatment with antag-
onists, adhesion of small preformed platelet aggregates to
HUVEC had to be considered. However, when platelets
were treated with the mAb P2 before thrombin activation
to prevent aggregate formation, platelet binding to HU-
VEC did not further decrease (data not shown). Thus, acti-
vated platelets that are unable to aggregate may still adhere
to HUVEC, perhaps by an additional binding mechanism.
However, blockade of b1 integrins, GPIba, GPIX, GPIV,
P-selectin, or PECAM-1 did not reveal an inhibitory ef-
fect.
Figure 8. Platelet adhesion to HUVEC monolayers after addition of
vWF and ristocetin. Resting (filled bars) and thrombin-activated platelets
(open bars) were allowed to adhere to HUVEC monolayers for 30 min in
the presence of 1 mg/ml vWF and increasing concentrations of ristocetin.
Platelet binding was then determined by flow cytometry as described
above. To test involvement of endothelial and platelet GPIba, HUVEC
and platelets were pretreated separately with 40 mg/ml anti–human
GPIba mAb, clone SZ2. Results are expressed as the mean 6 SD of the
median fluorescence (FL-1-H) of at least four experiments. *P ,0.01 and
**P ,0.05 by Student’s t test, compared with the corresponding controls
without vWF and ristocetin.
Figure 9. Proposed model of adhesion of activated platelets to HU-
VEC. Upon activation, platelet GPIIbIIIa receptors bind different adhe-
sive proteins, such as fibrinogen, vWF, and fibronectin. These proteins
are either present in plasma or secreted by the platelets themselves. De-
pendent upon the bound adhesive protein, adhesion of platelets to endo-
thelial cells is mediated by different endothelial counter receptors.
Whereas fibronectin binds only to avb3-integrin, fibrinogen binds to
ICAM-1 or avb3-integrin and vWF binds primarily to avb3-integrin or
possibly also to GPIba.336 Activated Platelet Adhesion to Endothelial Cells
We found that adhesive proteins play an important role
in activated platelet adhesion to HUVEC. Blockade of
platelet-exposed fibrinogen resulted in a significant de-
crease of bound platelets. Moreover, addition of fibrinogen
further increased platelet adhesion, indicating that platelets
may be able to use both endogenous and exogenous fibrin-
ogen to bind to endothelial cells. Importantly, blockade of
fibronectin and vWF, which are both also exposed on
GPIIbIIIa on activated platelets (29), decreased adhesion as
well. This is in accordance with previous studies showing
that platelet-released fibronectin and vWF are capable of
cross-linking platelets or platelets and tumor cells (35, 36).
It is conceivable that thrombospondin (TSP)-1, another
platelet-released adhesive protein, may also participate in
the binding to HUVEC. Although blockade of the major
TSP-1 receptor on platelets, GPIV (CD36), did not affect
platelet adhesion to HUVEC, treatment of platelets with
the anti–TSP-1 mAb 5G11 revealed a minimal inhibitory
effect (data not shown). This indicates that TSP-1 may be
bound by a different receptor, most likely GPIIbIIIa. How-
ever, because this inhibition was very modest and this mAb
does not block platelet aggregation (37), involvement of
TSP-1 remains uncertain.
The significant role of adhesive proteins in platelet adhe-
sion to HUVEC monolayers is further demonstrated by the
fact that binding was not observed when platelets were ac-
tivated without secretion by using zinc or manganese. Al-
though these cations activate the GPIIbIIIa receptor, only
the addition of exogenous fibrinogen allowed platelets to
bind to HUVEC or to form aggregates (30, 31), indicating
that platelet–platelet and platelet–HUVEC interactions are
mediated by the same bridging mechanism. Thus, it is pos-
sible that the reduced fluorescence of HUVEC after treat-
ment of platelets with anti-GPIIbIIIa antagonists may be
due to the reduction of platelet aggregates rather than of
platelet-HUVEC interactions. However, extensive platelet
aggregate formation was not observed on TEM, suggesting
that the inhibition was primarily due to blockade of platelet
adhesion to HUVEC.
Interestingly, evaluation of the HUVEC receptors in-
volved in activated platelet adhesion revealed participation
of three different receptors. Treatment of HUVEC with
RGD peptides resulted in the greatest inhibition of platelet
adhesion, suggesting that RGD-dependent adhesive pro-
tein receptors were predominantly involved. However,
blockade of b1 integrins on HUVEC did not affect platelet
adhesion. This is in accordance with a previous study
showing that a5b1 integrins serve as RGD-dependent fi-
brinogen receptors only when HUVEC are suspended, but
not attached (38). Under our experimental conditions,
avb3 integrin was the only RGD-binding receptor found
to be involved in platelet binding, although its blockade by
the mAb LM609 did not reduce platelet adhesion to the
level observed with RGD peptides. Similarly, two previous
reports have shown that platelet adhesion to activated en-
dothelial cells could be partly inhibited by the same anti-
avb3 mAb (11, 12). Because avb3 integrin binds different
adhesive proteins (39), it is likely that platelets bind to en-
dothelial avb3 integrin by forming bridges with fibrinogen,
fibronectin, and vWF.
Besides the binding site for b2 integrins, endothelial
ICAM-1 has recently been shown to contain an epitope for
the binding of fibrinogen that mediates the binding of leu-
kocytes (22, 40). We now present evidence that a compo-
nent of platelet binding to HUVEC uses this mechanism.
Treatment of HUVEC with the mAb 2D5, which blocks
the fibrinogen-binding site of ICAM-1, decreased binding
of activated platelets by z50%. The fact that the other
anti–ICAM-1 mAbs, that recognize either the epitope for
b2 integrins (R6.5 and 6E6) or rhinoviruses (VF27) also de-
creased platelet binding suggests some cross-reactivity with
the fibrinogen-binding region. This region has recently
been localized within the first Ig domain of ICAM-1 (41),
which is also involved in the aLb2-dependent binding of
leukocytes (42) and rhinoviruses (23).
Besides avb3 integrin and ICAM-1, we additionally found
evidence for involvement of endothelial GPIba in the
binding of activated platelets to HUVEC monolayers.
Platelet adhesion could be blocked significantly by treating
HUVEC with the anti-GPIba mAb SZ2. Furthermore,
addition of exogenous vWF increased platelet binding only
in the presence of ristocetin, which is known to allow solu-
ble vWF to interact with GPIba. Also, this vWF/ristoce-
tin-dependent binding of activated platelets to HUVEC
could be partially inhibited with the mAb SZ2. However,
the mAb 2E4, another blocking anti-GPIba mAb, did not
exhibit a significant inhibitory effect, raising some question
as to the significance of endothelial GPIba in platelet bind-
ing. Indeed, it has been debated whether HUVEC express
GPIba. Whereas one study has recently questioned the
synthesis of GPIba in HUVEC (43), other investigators
have found that GPIba on HUVEC participated in differ-
ent functions, including binding to vWF, binding of sickle
erythrocytes, and homotypic binding of HUVEC in the
presence of vWF and ristocetin (44–47). We found that
unstimulated HUVEC expressed GPIba at a modest level
when measured by flow cytometry with the mAb SZ2 and
2E4 (data not shown). Thus, based on our data, we con-
clude that platelet-exposed vWF may bind not only to
avb3 integrin but, in part, also to GPIba. The potential rel-
evance of this observation is enhanced by a recent study
showing that human endothelial cells also express GPIba in
vivo (48).
Although activated platelet adhesion to endothelial cells
was demonstrated some 20 years ago (2), the involvement
of either surface-bound or exposed intercellular matrix pro-
teins has not been conclusively evaluated. We believe that
our studies measuring platelet binding to HUVEC mono-
layers by flow cytometry convincingly demonstrate that ac-
tivated platelets can bind directly to endothelial cells rather
than to exposed intercellular matrix proteins. Moreover,
we present evidence that endothelial cell surface–associated
matrix proteins are likewise not involved in the binding of
activated platelets. Although suspended HUVEC were found337 Bombeli et al.
to express vWF, collagen IV, and fibronectin, platelet ad-
hesion to HUVEC monolayers was not inhibited by blocking
mAbs to these proteins. HUVEC-associated vWF and fi-
bronectin participated in platelet binding only when HUVEC
were detached and suspended before the addition of plate-
lets. Furthermore, we found that activated platelet adhesion
to HUVEC matrix (or to HUVEC in suspension) was me-
diated by platelet b1 integrins, whereas binding to conflu-
ent HUVEC monolayers was dependent upon GPIIbIIIa.
This participation of different platelet receptors in binding
to matrix versus cells further confirms that HUVEC-associ-
ated matrix proteins were not significantly involved in acti-
vated platelet binding to HUVEC monolayers.
It is notable that platelet adhesion was not affected by
blockade of platelet P-selectin, a major pathway for platelet
binding to leukocytes and tumor cells (49, 50). Both anti–
P-selectin mAbs G1 and WAPS12.2 have previously been
shown to block platelet adhesion and rolling, respectively
(6, 24). Similarly, neuraminidase-induced degradation of
endothelial sialylated glycoproteins that may be potential
endothelial ligands for platelet P-selectin also did not alter
platelet binding. Although in our assays HUVEC were not
stimulated by any exogenous agonists, platelet-induced
stimulation of HUVEC could not be excluded. Thus, we
additionally tested the contribution of activation-depen-
dent adhesion molecules, including P-selectin, E-selectin,
and VCAM-1. However, none of these proteins partici-
pated in the binding mechanism. This may be due, in part,
to the brief incubation with platelets (30 min), which may
have been too short to induce significant upregulation of
E-selectin and VCAM-1. Finally, PECAM-1 has recently
been proposed to participate in platelet binding to endo-
thelium (13). However, treatment of platelets and HUVEC
with two different anti–PECAM-1 mAbs produced only
minimal inhibition that was not significant.
As summarized in Fig. 9, our data provide evidence that,
similar to platelet aggregation, activated platelet adhesion to
HUVEC monolayers is mediated by a GPIIbIIIa-depen-
dent bridging mechanism, involving platelet-bound fibrin-
ogen, fibronectin, and vWF. Consequently, administration
of GPIIbIIIa-blocking drugs may inhibit not only the for-
mation of platelet aggregates, but also their adhesion to the
intact endothelium. This effect might be important, partic-
ularly in the microvasculature, as it has recently been shown
in an in vivo thrombosis model using the anti-GPIIbIIIa
mAb 7E3 (51). Furthermore, the involvement of the en-
dothelial cell receptors ICAM-1, avb3 integrin, and GPIba
in the binding of activated platelets suggests that blockade
of these receptors may have antithrombotic effects. Finally,
because these endothelial adhesion molecules are known to
become upregulated by various exogenous stimuli, endo-
thelial cell activation may further increase binding of acti-
vated platelets and thus contribute to a prothrombotic state.
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